New drug combo aims to reboot immune system against stubborn melanoma
NCT ID NCT04562129
Summary
This study is testing a combination of three immunotherapy drugs (Interleukin-2, ipilimumab, and nivolumab) for people with advanced, inoperable melanoma. It is specifically for patients whose cancer has continued to grow despite prior treatment with a common type of immunotherapy. The goal is to see if this new sequence of drugs can better control the cancer and extend survival.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MELANOMA STAGE III are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Moffitt Cancer Center
RECRUITINGTampa, Florida, 33612, United States
Contact
Contact
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
Conditions
Explore the condition pages connected to this study.